Prenetics Global (Prenetics Global) EBITDA Margin % : -278.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Prenetics Global's EBITDA for the three months ended in Dec. 2023 was $-14.67 Mil. Prenetics Global's Revenue for the three months ended in Dec. 2023 was $5.28 Mil. Therefore, Prenetics Global's EBITDA margin for the quarter that ended in Dec. 2023 was -278.00%.

Prenetics Global EBITDA Margin % Historical Data

The historical data trend for Prenetics Global's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global EBITDA Margin % Chart

Prenetics Global Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

-201.12

-2.17

-1,668.91

-1,656.30

-224.23

Prenetics Global Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial									-2,274.35	-61.56	-238.27	-260.87	-278.00

Competitive Comparison of Prenetics Global's EBITDA Margin %

For the Diagnostics & Research subindustry, Prenetics Global's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prenetics Global's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Prenetics Global's EBITDA Margin % falls into.

Prenetics Global EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Prenetics Global's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-48.755	/	21.743
	=	-224.23 %

Prenetics Global's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-14.67	/	5.277
	=	-278.00 %

Prenetics Global (NAS:PRE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Prenetics Global EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.